Page 231 - Programme book for The International Liver Congress 2015, EASL ILC 2015

P0643 SERUM HBV RNA IS AN EARLY PREDICTOR OF HBEAG ePOSTERS
P0644 SEROCONVERSION IN PATIENTS WITH CHRONIC
P0645 HEPATITIS B (CHB) TREATED WITH PEG-INTERFERON
P0646 ALPHA-2A (40KD)
P0647 Florian van Bömmel*, Alena van Bömmel, Alexander Krauel, Hua He,
Cynthia Wat, Vedran Pavlovic, Danilo Deichsel, Thomas Berg,
Stephan Böhm, Germany

HCC RISK SCORES: APPLICATION OF THE CU-HCC, GAG-
HCC AND PAGE-B SCORES TO CHRONIC HEPATITIS B
(CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL
FUMARATE (TDF)
W. Ray Kim*, Rohit Loomba, Thomas Berg, Raul Aguilar Schall,
Leland Yee, Phillip Dinh, John F. Flaherty, Eduardo B. Martins,
Ira Jacobson, Scott Fung, Selim Gurel, Maria Buti, Patrick Marcellin,
The United States

NON-SYNONYMOUS SINGLE-NUCLEOTIDE
POLYMORPHISMS (SNPS) IN TLR7 DO NOT IMPACT GS-9620
DEPENDENT TLR7 ACTIVATION
Indrani Rebbapragada*, Gabriel Birkus, Jason Perry, Stefan Pflanz,
The United States

LOWER RISK OF HEPATOCELLULAR CARCINOMA IN
CHRONIC HEPATITIS B PATIENTS TREATED WITH
ENTECAVIR: A REACH-B ANALYSIS OF THE ENUMERATE
STUDY
Joseph Ahn*, Mindie Nguyen, Hannah Lee, Joseph Lim, Calvin Pan,
Helen Te, Tram Tran, Huy N. Trinh, Daryl Lau, Danny Chu, Albert Min,
Truong-Sinh Leduc, Anjana Pillai, Ho Bae, Son Do, Ajitha Mannalithara,
Anna S. Lok, W. Ray Kim, The United States

PROACTIVE DOSE ADJUSTMENTS ARE NECESSARY IN
MANY ADV-EXPERIENCED PATIENTS TREATED WITH TDF
MONOTHERAPY FOR 5 YEARS: A PROSPECTIVE COHORT
STUDY IN 320 PATIENTS
Pietro Lampertico*, Roberta Soffredini, Marta Borghi, Mauro Viganò,
Floriana Facchetti, Enrico Galmozzi, Federica Invernizzi,
Massimo Colombo, Italy

Vienna, Austria • April 22–26, 2015 231